BUYRAK TOSH KASALLIKLARINI KONSERVATIV DAVOLASHDA ALLOPURINOLNING AHAMIYATI
Keywords:
Buyrak tosh kasalligi, allopurinol, giperurikemiya, purin metabolizmi.Abstract
Buyrak tosh kasalliklari bu siydik yo‘llarida turli turdagi kristallarning to‘planishi bilan kechadigan keng tarqalgan urologik patologiya bo‘lib, bemorlarning hayot sifatiga sezilarli ta’sir ko‘rsatadi. Konservativ davolash usullarida allopurinol preparati muhim o‘rin tutadi [2], chunki u purin metabolizmini ingibir qilish orqali siydikda xursin va oksalat turidagi toshlar hosil bo‘lishini sezilarli darajada kamaytiradi. Shu bilan birga, allopurinol podagra va hiperurikemiya holatlarida ham samarali bo‘lib, kasallikning takrorlanish xavfini pasaytiradi[5 ]. Preparatni qo‘llash nafaqat toshlarning kattalashishini to‘xtatadi, balki ularni bartaraf etish jarayonini ham yengillashtiradi[4]. Konservativ davolash samaradorligini oshirish maqsadida allopurinol bilan birga bemorlarga dieta rejimi va suyuqlik qabul qilishni nazorat qilish tavsiya etiladi[1]. Shuningdek, preparatning dozalari va qo‘llanish strategiyasi yosh guruhlari — bolalar, kattalar va qariyalar — bo‘yicha farqlanadi, va yon ta’sirlari ham doimiy nazorat talab qiladi[3]. Bu kasallik bilan kasallanganlarda og‘riq juda kuchli bo‘lgan[6].
References
1. Ferrari L, Meschi M, Musini S, Frattini A, Savazzi GM. Eziopatogenesi e clinica della nefrolitiasi, oggi [Etiopathogenesis and clinical aspects of nephrolithiasis--at present]. Recenti Prog Med. 2003 Mar;94(3):136-41. Italian. PMID: 12677782.
2. Geraghty R, Lovegrove C, Howles S, Sayer JA. Role of Genetic Testing in Kidney Stone Disease: A Narrative Review. Curr Urol Rep. 2024 Dec;25(12):311-323. doi: 10.1007/s11934-024-01225-5. Epub 2024 Aug 3. PMID: 39096463; PMCID: PMC11374836.
3. Miller AW, Penniston KL, Fitzpatrick K, Agudelo J, Tasian G, Lange D. Mechanisms of the intestinal and urinary microbiome in kidney stone disease. Nat Rev Urol. 2022 Dec;19(12):695-707. doi: 10.1038/s41585-022-00647-5. Epub 2022 Sep 20. PMID: 36127409; PMCID: PMC11234243.
4. Pak CY. Medical prevention of renal stone disease. Nephron. 1999;81 Suppl 1:60-5. doi: 10.1159/000046300. PMID: 9873216.
5. Tung KH, Tan EC, Foo KT. Chemolysis of uric acid stones. Ann Acad Med Singap. 1984 Oct;13(4):620-4. PMID: 6099081.
6. Thongprayoon C, Krambeck AE, Rule AD. Determining the true burden of kidney stone disease. Nat Rev Nephrol. 2020 Dec;16(12):736-746. doi: 10.1038/s41581-020-0320-7. Epub 2020 Aug 4. PMID: 32753740.
